222 related articles for article (PubMed ID: 24098331)
1. A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity.
Wright DW; Deuzing IP; Flandre P; van den Eede P; Govaert M; Setiawan L; Coveney PV; Marcelin AG; Calvez V; Boucher CA; Beerens N
PLoS One; 2013; 8(10):e74078. PubMed ID: 24098331
[TBL] [Abstract][Full Text] [Related]
2. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
3. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics study of HIV-1 RT-DNA-nevirapine complexes explains NNRTI inhibition and resistance by connection mutations.
Vijayan RS; Arnold E; Das K
Proteins; 2014 May; 82(5):815-29. PubMed ID: 24174331
[TBL] [Abstract][Full Text] [Related]
5. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
6. A novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs.
Zhang XM; Wu H; Zhang Q; Lau TC; Chu H; Chen ZW; Jin DY; Zheng BJ
J Antimicrob Chemother; 2015 May; 70(5):1381-90. PubMed ID: 25637519
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
Menéndez-Arias L; Betancor G; Matamoros T
Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
[TBL] [Abstract][Full Text] [Related]
8. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.
Delviks-Frankenberry KA; Nikolenko GN; Barr R; Pathak VK
J Virol; 2007 Jul; 81(13):6837-45. PubMed ID: 17428874
[TBL] [Abstract][Full Text] [Related]
9. Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors.
Tanuma J; Hachiya A; Ishigaki K; Gatanaga H; Lien TT; Hien ND; Kinh NV; Kaku M; Oka S
Microbes Infect; 2010 Dec; 12(14-15):1170-7. PubMed ID: 20713171
[TBL] [Abstract][Full Text] [Related]
10. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
12. Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6.
Corona A; Meleddu R; Esposito F; Distinto S; Bianco G; Masaoka T; Maccioni E; Menéndez-Arias L; Alcaro S; Le Grice SF; Tramontano E
PLoS One; 2016; 11(1):e0147225. PubMed ID: 26800261
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.
Hachiya A; Marchand B; Kirby KA; Michailidis E; Tu X; Palczewski K; Ong YT; Li Z; Griffin DT; Schuckmann MM; Tanuma J; Oka S; Singh K; Kodama EN; Sarafianos SG
J Biol Chem; 2012 Aug; 287(35):29988-99. PubMed ID: 22761416
[TBL] [Abstract][Full Text] [Related]
14. Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.
Delviks-Frankenberry KA; Lengruber RB; Santos AF; Silveira JM; Soares MA; Kearney MF; Maldarelli F; Pathak VK
Virology; 2013 Jan; 435(2):433-41. PubMed ID: 23068886
[TBL] [Abstract][Full Text] [Related]
15. Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine.
Delviks-Frankenberry KA; Nikolenko GN; Maldarelli F; Hase S; Takebe Y; Pathak VK
J Virol; 2009 Sep; 83(17):8502-13. PubMed ID: 19553318
[TBL] [Abstract][Full Text] [Related]
16. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
Hachiya A; Kodama EN; Sarafianos SG; Schuckmann MM; Sakagami Y; Matsuoka M; Takiguchi M; Gatanaga H; Oka S
J Virol; 2008 Apr; 82(7):3261-70. PubMed ID: 18216099
[TBL] [Abstract][Full Text] [Related]
17. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of HIV reverse transcriptase inhibition by zinc: formation of a highly stable enzyme-(primer-template) complex with profoundly diminished catalytic activity.
Fenstermacher KJ; DeStefano JJ
J Biol Chem; 2011 Nov; 286(47):40433-42. PubMed ID: 21953456
[TBL] [Abstract][Full Text] [Related]
19. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
Xu HT; Colby-Germinario SP; Oliveira M; Han Y; Quan Y; Zanichelli V; Wainberg MA
J Virol; 2014 Feb; 88(3):1536-47. PubMed ID: 24227862
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
